Feb 14, 2022 7:00 am EST Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022
Feb 7, 2022 7:00 am EST Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Feb 3, 2022 7:00 am EST Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases
Jan 13, 2022 5:00 pm EST Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors
Jan 12, 2022 7:00 am EST Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma
Jan 10, 2022 7:00 am EST Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results
